Progyny (PGNY) Research & Development (2018 - 2026)

Progyny (PGNY) has reported Research & Development for 9 consecutive years, with $18.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 1.8% year-over-year to $18.1 million in Q2 2026; TTM through Jun 2026 was $70.9 million, a 3.83% increase from a year earlier, with the FY2025 full-year figure at $72.1 million, up 12.77% from the prior year.
• Research & Development was $18.1 million for Q2 2026 at Progyny, up from $16.9 million in the prior quarter.
• Over five years, Research & Development peaked at $18.4 million in Q2 2025 and troughed at $10.0 million in Q1 2022.
• A 5-year average of $15.3 million and a median of $15.5 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 185.4% in 2022 and decreased 5.07% in 2026, its largest moves.
• Over 5 years, Research & Development stood at $13.0 million in 2022, then gained by 14.88% to $14.9 million in 2023, then rose by 4.73% to $15.6 million in 2024, then gained by 15.18% to $18.0 million in 2025, then climbed by 0.48% to $18.1 million in 2026.
• The last three Research & Development figures came in at $18.1 million (Q2 2026), $16.9 million (Q1 2026), and $18.0 million (Q4 2025), per Business Quant data.